Exelixis Presents Final Overall Survival Results From Phase 3 Contact-02 Pivotal Study Evaluating Cabozantinib in Combination With an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at Esmo 2024
伊克力西斯在Esmo 2024展示了第3期Contact-02關鍵研究中卡波替尼聯合一種免疫檢查點抑制劑治療轉移性去勢抵抗性前列腺癌的最終總生存期結果